Aged Garlic Extract Study

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

Le lien est enregistré dans le presse-papiers

StatutTerminé

Les sponsors

Lund University Hospital

ESSAI CLINIQUE: NCT03860350

BioSeek: NCT03860350

Mots clés

Abstrait

The primary intention of the study is to examine the effect of aged garlic extract (AGE) on the absolute change in coronary artery calcium (CAC). The second intention is to examine the effect of AGE on inflammatory biomarkers and microcirculation. It is a double blind placebo controlled study. The participants will ingest AGE during a period of one year. The CAC will be controlled by computer tomography (CT) scan; the inflammatory biomarkers through blood sample test and the microcirculation through laser speckel imagining and laser doppler before and after the one year period of AGE ingestion.

La description

Objectives:

Effect on coronary artery atherosclerosis / the progression of atherosclerosis Effect on inflammatory and oxidation biomarkers Cholesterol lowering effect Effect on microcirculation

Type of study:

Randomized double blind controlled trial

Number of patients: 80 patients

Duration of the study:

The patients will be studied for one year after they have entered the study. The total time of the study duration from the including date of the first patient to the analysis of the last patient entering the study estimated to be 2-3 years. An inclusion rate off 1 to 2 patients per week.

Treatment:

Dose: Treated with a placebo capsule or a capsule containing a total of AGE 2400 mg daily for 1 year (2 Kyolic capsule (600 mg) twice daily).

Methods:

Placebo-controlled double blind randomized trial to determine whether AGE can influence the rate of atherosclerosis plaque burden measured by coronary artery calcium, improve vascular function and microcirculation and favorably change biomarkers of oxidative stress.

Randomization:

The participants are assigned to AGE or placebo in a double-blinded manner, using numbered containers assigned to a computer-generated randomization chart by a nurse coordinator.

Rendez-vous

Dernière vérification:	05/31/2019
Première soumission:	02/25/2019
Inscription estimée soumise:	02/27/2019
Première publication:	02/28/2019
Dernière mise à jour soumise:	06/07/2019
Dernière mise à jour publiée:	06/10/2019
Date de début réelle de l'étude:	11/30/2016
Date d'achèvement primaire estimée:	05/31/2019
Date estimée d'achèvement de l'étude:	05/31/2019

Condition ou maladie

Coronary Artery Disease

Microcirculation

Biomarkers

Intervention / traitement

Dietary Supplement: Aged Garlic Extract

Dietary Supplement: Placebo

Phase

Groupes d'armes

Bras	Intervention / traitement
Active Comparator: Aged Garlic Extract The participants will ingest 600 mg of Aged Garlic Extract in two capsules two times a day i.e. 1200 mg/day during a period of one year.	Dietary Supplement: Aged Garlic Extract
Placebo Comparator: Placebo The participants will ingest 600 mg of placebo in two capsules two times a day i.e. 1200 mg/day during a period of one year.	Dietary Supplement: Placebo

Critère d'éligibilité

Âges éligibles aux études	40 Years À 40 Years
Sexes éligibles à l'étude	All
Accepte les bénévoles en santé	Oui
Critères	Inclusion Criteria: - CAC score >10 - Framingham risk score (10 % or above) - Subjects are required to be on stable concomitant medications for at least 12 weeks prior to randomization - Subjects with diabetic must have HbA1C < 8.0, and stable HbA1C level variation range within 0.5% for three months. Exclusion Criteria: - Hypersensitivity to AGE therapy, - Unstable medical, psychiatric, or substance abuse disorder that may interfere with continuation in the study, - Weight ≥325 pounds, - Bleeding disorder, - History of myocardial infarction, - Stroke - Life-threatening arrhythmia within prior 6 months, - Resting hypotension (systolic < 90 mmHg) or hypertension (resting blood pressure >170/110) - Heart failure NYHA class III or IV, - History of malignancy within the last 5 years (other than skin cancer) or evidence of active cancer which would require concomitant cancer chemotherapy - Serum creatinine >1.4 mg/dl - Triglycerides > 400 at baseline visit - Diabetic subjects with HbA1C > 8 %, - Drug or alcohol abuse - Conditions interfering with accurate assessment of coronary calcification (metal clips, bypass patients, intracoronary stents) and drug absorption (partial ileal bypass or malabsorption syndrome). - Current use of anticoagulants (except for antiplatelet agents) - Chronic renal failure - Liver failure - Hematological or biochemical values at baseline visit outside the reference ranges considered as clinically significant.

Résultat

Mesures des résultats primaires

1. Change in coronary artery calcium (CAC) score [One year]

CAC is to be defined as a plaque of at least three contiguous pixels (area 1.02 mm 2) with a density of > 130 Hounsfield units. The lesion score are to be calculated by multiplying the lesion area by a density factor derived from the maximal Hounsfield unit within this area, as described by Agatston S, Janowitz WR, Hildner FJ et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15: 827-832. CAC score is measured at baseline and after one year follow-up and the difference is calculated.

Mesures des résultats secondaires

1. The changes in inflammatory biomarkers. [One Year]

Changes in C-reactive protein (CRP mg/L)

2. The changes in Interleukin-6 (IL-6) [One Year]

Changes in IL-6 (ng/L)

3. The changes in inflammatory biomarkers. [One Year]

Changes in Homocystein (µmol/L)

4. The changes in the microcirculation measured by Laser Doppler velocimetry [One Year]

Laser Doppler Flowmetry (LDF) is a non-invasive method to estimate the blood perfusion in the microcirculation. The advantage of the technique is that LDF provide a continuous or near continuous record of the microvascular blood flow. No current laser Doppler instrument can present absolute perfusion values (e.g. ml/min/100 gram tissue). Measurements are expressed as perfusion units (PU) which are arbitrary. The changes in PU will be measured.

5. Changes in Low Density Lipoprotein [One Year]

Changes of Low Density Lipoprotein (LDL) mmol/L

6. Changes in Triglycerides [One Year]

Changes of Triglycerides mmol/L.

7. Changes in Cholesterol [One Year]

Changes of cholesterol mmol/L.

8. Changes in High Density Lipoprotein [One Year]

Changes of High Density Lipoprotein(HDL) mmol/L,

9. Changes in lipid profile [One Year]

Apolipoprotein B (mmol/L)/Apolipoprotein A1 (mmol/L)

10. Changes in blood sugar [One Year]

Changes in fastening blood glucose measured as mmol/L

11. Changes in Blood pressure [One Year]

Changes of blood pressure Systolic and Diastolic presented as mmHg.

12. Changes in BMI [One Year]

Changes in BMI measured as weight (kg) and height (m) and will be combined to report BMI in kg/m^2